---
title: "The biopharmaceutical sector sees a short-term surge, PLBIO hits the limit up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244178895.md"
description: "The biopharmaceutical sector saw a short-term surge, with PLBIO hitting the limit up, followed by RemeGen, CCHT, JUNSHI BIO, ACROBIOSYSTEMS, and INNOCARE rising as well"
datetime: "2025-06-12T05:05:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244178895.md)
  - [en](https://longbridge.com/en/news/244178895.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244178895.md)
generator: "portal-rs"
---

# The biopharmaceutical sector sees a short-term surge, PLBIO hits the limit up

The biopharmaceutical sector saw a short-term surge, with PLBIO hitting the limit up, followed by RemeGen, CCHT, JUNSHI BIO, ACROBIOSYSTEMS, and INNOCARE also rising

### Related Stocks

- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)
- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [301080.CN](https://longbridge.com/en/quote/301080.CN.md)
- [000403.CN](https://longbridge.com/en/quote/000403.CN.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [000661.CN](https://longbridge.com/en/quote/000661.CN.md)

## Related News & Research

- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares](https://longbridge.com/en/news/296370263.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 million](https://longbridge.com/en/news/296243257.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**